PEPG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PepGen Inc (PEPG) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently trading in a bearish trend, and while there are some positive catalysts such as insider buying and analyst optimism, the financial performance and technical indicators suggest caution. The lack of recent news and weak financials further support a hold recommendation.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. MACD is positive at 0.0996, indicating slight bullish momentum, but RSI is neutral at 24.025. Key support and resistance levels are S1: 1.571 and R1: 1.769, with the current pre-market price at 1.58, close to the support level. The stock has a 60% chance to decline -2.12% in the next day and -1.65% in the next week, suggesting limited short-term upside.
Insider buying has increased significantly by 294713.82% in the last month.
Analysts have given optimistic ratings, with Oppenheimer setting a $15 price target and Guggenheim raising the target to $
Potential positive data from the FREEDOM2 trial in March could act as a catalyst.
Financials are weak, with Q4 2025 showing no revenue, a net income drop of -17.54% YoY, and EPS down -60.29% YoY.
Concerns over kidney safety risks in the DM1 program remain unresolved.
The stock is in a bearish technical trend with limited short-term upside potential.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$18.34M (-17.54% YoY), and a significant EPS drop of -60.29% YoY. Gross margin remains at 0%. These figures indicate poor financial health and limited growth prospects.
Analysts are cautiously optimistic. Oppenheimer initiated coverage with an Outperform rating and a $15 price target, citing potential best-in-class efficacy for DM1. Guggenheim raised its price target from $6 to $7, citing positive expectations from the FREEDOM2 trial. However, safety concerns and weak financials temper this optimism.
